Global scenario of counterfeit antimalarials: A potential threat

Area of Science:

• Global Health
• Pharmaceutical Sciences
• Infectious Diseases

Background:

• Malaria causes over 1 million deaths annually, with antimalarials being a key treatment strategy.
• Counterfeit antimalarials undermine treatment efficacy, erode public trust, and drive parasite drug resistance.
• These falsified medicines also impede innovation and intellectual property protection in pharmaceutical development.

Purpose of the Study:

• To review the global prevalence of counterfeit antimalarial drugs.
• To discuss methods for detecting substandard and falsified antimalarials.
• To explore strategies for combating the proliferation of counterfeit antimalarial medicines.

Main Methods:

• A comprehensive literature search was conducted using databases like PubMed, Google, and International Pharmaceutical Abstracts.
• Keywords included 'counterfeit antimalarials,' 'substandard,' 'falsified,' and 'drug resistance.'
• Analysis focused on prevalence data, detection techniques, and anticounterfeiting measures.

Main Results:

• The majority of studies on counterfeit antimalarials were concentrated in Southeast Asia and Africa.
• Prevalence rates of substandard antimalarials were reported as high as 88.4% in Africa and 53% in Southeast Asia.
• Significant geographical disparities in prevalence underscore the urgent need for targeted interventions.

Conclusions:

• A multifaceted approach involving pre- and post-marketing surveillance is crucial to prevent the entry of falsified antimalarials.
• Regulatory bodies must rigorously examine pharmaceutical samples to ensure quality.
• Strict legislation and enforcement are essential to maintain the integrity and therapeutic value of antimalarial medicines.